Literature DB >> 6199357

A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests.

R Barth, H Gruschkau, U Bijok, J Hilfenhaus, J Hinz, L Milcke, H Moser, O Jaeger, H Ronneberger, E Weinmann.   

Abstract

A new inactivated rabies vaccine (purified chick embryo cell vaccine) has been developed using the Flury LEP-C 25 strain of rabies virus propagated in primary chick embryo cell cultures. The antigen was purified and concentrated by continuous density gradient centrifugation and inactivated by betapropiolactone. This vaccine was tested for innocuity, tolerability and protective capacity in a series of laboratory tests and compared with human diploid cell strain (HDC)-vaccines of similar antigenicity. The results indicated that this new vaccine was excellently tolerated and that its protective activity met the high standard of HDC-vaccine, conditions which were imposed on this vaccine before entering clinical trials in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199357     DOI: 10.1016/s0092-1157(84)80019-0

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  9 in total

1.  In pursuit of the perfect rabies vaccine.

Authors:  S D Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-30

2.  Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis.

Authors:  Hardanahalli S Ravish; Veena Vijayashankar; Shampur N Madhusudana; Mysore K Sudarshan; Doddabele Ha Narayana; Gangaboraiah Andanaiah; Belludi Y Ashwin; Annadani R Rachana; Manjula Shamanna
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis.

Authors:  P Suntharasamai; M J Warrell; C Viravan; P Chanthavanich; S Looareesuwan; A Supapochana; J K Supanaranond; S Chittamas; U Bijok; D A Warrell
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

4.  Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.

Authors:  Doddabele Hanumanthaiah Ashwath Narayana; Shampur Narayana Madhusudana; Gadey Sampath; Radhe Madhab Tripathy; Mysore Kalappa Sudarshan; Haradanahalli Shankaraiah Ravish; Durga Madhab Satapathy; Giriyanna Gowda; Ramesh Holla; Belludi Yajman Ashwin; Asutosh Padhi; Shamanna Manjula; Pradip Maganlal Patel
Journal:  Hum Vaccin Immunother       Date:  2013-09-12       Impact factor: 3.452

Review 5.  Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential.

Authors:  Shimao Zhu; Caiping Guo
Journal:  Viruses       Date:  2016-10-28       Impact factor: 5.048

Review 6.  Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies.

Authors:  Nicole Armbruster; Edith Jasny; Benjamin Petsch
Journal:  Vaccines (Basel)       Date:  2019-09-27

7.  Change in the Single Amino Acid Site 83 in Rabies Virus Glycoprotein Enhances the BBB Permeability and Reduces Viral Pathogenicity.

Authors:  Chunfu Li; Yongzhi Wang; Huiting Liu; Xinghua Zhang; Dalai Baolige; Shihua Zhao; Wei Hu; Yang Yang
Journal:  Front Cell Dev Biol       Date:  2021-02-09

8.  Sequencing and molecular characterization of CTNCEC25, a China fixed rabies virus vaccine strain CTN-1 adapted to primary chicken embryo cells.

Authors:  Shimao Zhu; Chunhua Wang; Pei Zhang; Hui Li; Shan Luo; Caiping Guo
Journal:  Virol J       Date:  2014-10-06       Impact factor: 4.099

9.  An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs.

Authors:  Margit Schnee; Annette B Vogel; Daniel Voss; Benjamin Petsch; Patrick Baumhof; Thomas Kramps; Lothar Stitz
Journal:  PLoS Negl Trop Dis       Date:  2016-06-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.